Our CEO Laura has been nominated and selected as one of the three finalists for KAUTE Foundation's Young Research Entrepreneur of the Year award. This is already her second nomination for the award. 

The premier news outlet in Finland, Yle, did an extensive news feature article about StemSight, including a video filmed at our research labs. The video was also aired in local news. 

As part of StemSight's pledge to help patients suffering from Limbal Stem Cell Deficiency, we hosted our first ever public symposium on rare corneal disorders in Tampere University Arvo building. The symposium hosted speakers from Tampere University ophthalmology research groups, StemSight, and the local patient advocacy group. As a highlight of the symposium, we heard from a special patient case: 5-year-old Lauri, who suffers from the rare congenital KID-syndrome, which has resulted in LSCD in both of his eyes. The symposium was inspired by Lauri's family's outreach to StemSight, and we were very grateful to have them present at the event.

StemSight has licensed the CRISPR/Cas9 foundational intellectual property for use of the technology as part of our therapeutic platform from ERS Genomics. This Nobel-winning technology, known as "genetic scissors" allows selective knock-out of particular target genes in wanted cells. Using this technology to modify iPS cells allows the trait to be passed on to the resulting therapeutic cells. 

We kick off 2024 at the world's biggest healthcare investment event, JP Morgan in San Francisco. This marks our first time at the premier partnering event, which often sets the healthcare industry's market sentiment for the new year. Our CEO Laura has a packed agenda of partnering meetings with pharma companies and fellow biotechs, as well as network building to fuel our global ambitions.

Our CEO and founder Laura Koivusalo celebrates the 106th Independence Day of Finland in the President's Castle. Recognized as a young innovator and leader in accordance with this year's theme "Changing times", Laura is honored to be invited to this most glamorous event of the year! Laura's gown was designed and made by Finnish Vimma Company's designer Sima Salmani, and it highlighted StemSigh't work in eye research. The "eye-catching" dress certainly made a splash in Finnish media!

Our CEO Laura Koivusalo gave insights from the trenches of cell therapy drug development in the "New Modalities" Super Session on the 1st day of Nordic Life Science days on Nov 29. On the panel, she joined representatives from the European Medicines Agency and the Canadian Centre for Regenerative Medicine.

We are excited to announce that Dr Ross Macdonald - former CEO of Cynata Therapeutics - joins our leadership team, bringing valuable commercial experience from the iPS cell therapy industry. Read the full press release here.

Altogether 17 companies from different sectors were selected to Business Finland's new pilot funding program Deep Tech Accelerator. The total funding consists of two phases, the first of which is an EUR 400.000 grant and the second an EUR 1 million loan.

Altogether 17 companies from different sectors were selected to Business Finland's new pilot funding program Deep Tech Accelerator. The total funding consists of two phases, the first of which is an EUR 400.000 grant and the second an EUR 1 million loan.

The Finnish Research Impact Foundation (Vaikuttavuussäätiö) has awarded StemSight and Tampere University's joint Tandem Industry Academia 2-year project.

At the EIT Health catapult finals held in Munich on the 20th of June at the Bits & Pretzels Healthtech, StemSight won 10,000 € cash for third place in the Biotech category, and the Merck prize for the best emerging biotech. 

The 75,000 € WomenTechEU grant is awarded by the European Commission to innovative deep-tech companies founded and lead by women. For more information and the full list of award recipiants, see here.

StemSight has been selected as one of the three finalists in Biotech category for the EIT Health Catapult competition and training program. The finals will be held in Munich on the 20th of June at the Bits & Pretzels Healthtech. 

The Biotech category semifinalist pitches are now live on the EIT Health Catapult platform on-demand. Register here for free to see all the pitches. The finalists will be announced later in the Spring, and the top companies will present live at the Bits and Pretzels Healthtech event in Munich in June.

The global Junior Chamber International organization selects StemSight CEO Laura among this year's Ten Outstanding Young Persons of the World. Amazing news!

StemSight has been selected as the winner from Finland in the Silicon Vikings New Nordics pitching competition. The Nordic and Baltic finalists will compete against each other in the Grand Finals during Slush Week in November.

StemSight has been selected among the 14 European Biotech startups selected to compete in the semifinals of EIT Health's Catapult programme. Each year, the competition showcases Europe’s most promising biotech, medtech and digital health start-ups to leading experts and investors. 

StemSight was selected among the best presenting companies in two consecutive events organized by Tech Tour. The European Healthtech Investment Forum and the Future22 flagship event for the very best innovative companies.

StemSight received the 50 000 € Silmu grant from Instrumentarium Science Foundation. The foundation has a long history in supporting research in medical technologies and life science.

Business Finland, Spinverse and Technology Industry Finland have selected our CTO and founder, Prof. Heli Skottman as one of the three finalists for the 2nd Innovation Professor of the Year award. We're very proud of her!

Our CEO, Dr. Laura Koivusalo has been selected as one of the Outstanding Young Persons of the Year by Junior Chamber International Finland. Laura was selected from the category of Medical Innovation, and the selection committee highlighted her merits in academic research, startup entrepreneurship as well as her volunteer work.

Following the press release of StemSight's investment, the prime European startup media Sifted did a great piece on the future of stem cell therapies to cure blindness, by interviewing our CEO Laura.

We are proud to announce the successful pre-seed funding round lead by Finnish deep-tech VC Voima Ventures and Avohoidon tutkimussäätiö. This funding goes to further development of StemSight's cell therapy product for limbal stem cell defiency.

​The Finnish Centre for Economic Development has granted 190 k€ in funding for advancement of StemSight's limbal stem cell deficiency product development. The funding is part of EU's regional development funding.